The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021
Life Sciences M&A Was Almost Half Of 2019’s Record
COVID-19 drove down both deal-making and biopharma “firepower” for part of 2020, but the industry began rebounding. This year should see significant bolt-on M&A activity and technology-driven alliances, according to EY.
You may also be interested in...
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.